Global Menstrual Cramps Treatment Market is Growing with 7.8% CAGR in the Forecast Period of 2021 to 2028

Global Menstrual Cramps Treatment Market is growing with factors such as rising technological advancement and increasing research and development for developing innovative drugs. Rise in awareness about dysmenorrhea also acts as a major factor for the growth of the market. Increasing number of treatment options has also given a boom to the global menstrual cramps treatment market.

Rising disposable income has propelled the demand of the market. However, substantial morbidity of dysmenorrhea which leads to inadequate treatment has decreased the demand of the market.

Global Menstrual Cramps Treatment Market Scenario             

According to Data Bridge Market Research, the market for global menstrual cramps treatment in North America has the highest market share followed by Europe and Asia-Pacific. Market leader is GlaxoSmithKline Plc. which accounts an estimated market share of approximately 5.70% in the global market. The company has gained outstanding sale by providing wide range of menstrual cramps treatment market product.

  • In March 2018, GlaxoSmithKline Plc. declared the successful agreement with Novartis to acquire full ownership of consumer healthcare business. This agreement helped company to escalate product portfolio and revenue growth of the company.

Menstrual Cramps Treatment MarketTrends Impacting the Market

Now the question is which other regions GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc. (A subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd.) are targeting? Data Bridge Market Research has forecasted a large growth in North America menstrual cramps treatment market and the market leaders are targeting U.S. and Canada to be their next pocket revenue for 2021.

The global menstrual cramps treatment market is becoming more competitive with companies such as GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc. (A subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd.), AbbVie Inc., Mylan N. V. (A part of Viatris Inc.). These are the top dominating companies in menstrual cramps treatment market and are launching more new therapies in the market. The data bridge market research new reports highlight the major growth factors and opportunities in the global menstrual cramps treatment market.

For more analysis on the global menstrual cramps treatment market request for a briefing with our analysts https://www.databridgemarketresearch.com/reports/global-menstrual-cramps-treatment-market

New Market Developments

  • In July 2020, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), which holds Takeda a joint business venture in the Japanese market, announced a new strategy for its local commercial operations. This strategy has enhanced the company's presence in the Japanese market and propels its revenue growth.
  • In July 2019, AbbVie Inc. submitted a New Drug Application (NDA) to the FDA for elagolix in combination with estradiol/norethindrone acetate (E2/NETA) daily add-back therapy for the management of heavy menstrual bleeding associated with the uterine fibroids. This submission has accelerated the further research and development of the company.

Scope of the Global Menstrual Cramps Treatment Market

Global menstrual cramps treatment market is segmented on the basis of countries into the U.S., Canada and Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam and rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and rest of Middle East and Africa, Brazil, Argentina, Peru and rest of South America.

  • All country based analysis of the global menstrual cramps treatment market is further analyzed based on maximum granularity into further segmentation. On the basis of type, the menstrual cramps treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. On the basis of treatment type, the menstrual cramps treatment market is segmented into medication, therapy, surgery and others. On the basis of mode of prescription, the menstrual cramps treatment market is segmented into prescription and over the counter. On the basis of route of administration, the menstrual cramps treatment market is segmented into oral, parenteral, implants and others. On the basis of end user, the menstrual cramps treatment market is segmented into hospitals, ambulatory surgical centers, specialty centers and others. On the basis of distribution channel, the menstrual cramps treatment market is segmented into direct tender, retail sales, pharmacies and others.

To know more about the study https://www.databridgemarketresearch.com/reports/global-menstrual-cramps-treatment-market

Key Pointers Covered in Global Menstrual Cramps Treatment Market Industry Trends and Forecast to 2028

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries
  • Market value and over view of menstrual cramps treatment market
  • Company profiling of top eight players of menstrual cramps treatment market

Key Market Competitors Covered in the Report

  • Bayer AG
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd.)
  • Color Seven Co., Ltd.
  • Beurer GmbH
  • Mylan N. V. (A part of Viatris Inc.)
  • Boehringer Ingelheim International GmbH
  • PMS4PMS, LLC
  • Sanofi
  • Nobelpharma Co., Ltd.
  • ObsEva
  • Myovant Sciences Ltd.
  • AbbVie Inc.
  • BioElectronics Corporation
  • LIVIA
  • Alvogen
  • Cumberland Pharmaceuticals Inc.
  • Lupin Pharmaceuticals, Inc. (A subsidiary of LUPIN)
  • Janssen Pharmaceuticals, Inc. (A subsidiary of Johnson & Johnson Services, Inc.),
  • Sun Pharmaceutical Industries Ltd.

Above are the key players covered in the report, to know about more and exhaustive list of menstrual cramps treatment companies’, contact us https://www.databridgemarketresearch.com/toc/?dbmr=global-menstrual-cramps-treatment-market

Research Methodology: Global Menstrual Cramps Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Manufacturer, Healthcare Industry, Scientists, Research Laboratories
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others

Related Reports

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/